A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Launched by REGENERON PHARMACEUTICALS · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking into the long-term health effects of two experimental drugs, fianlimab and cemiplimab, for adults who have advanced melanoma, a type of skin cancer. If you participated in a previous study (R3767-ONC-1613), specifically in cohorts 6, 15, or 16, you may be eligible to join this new study. The goal is to see how safe and effective these drugs are over time, but it's important to note that no new study drugs will be given during this trial. Instead, your cancer status will be monitored along with your general health and any other treatments you may have received since your last participation.

If you decide to take part, you won't be receiving any active treatment, but your health will be tracked closely to gather valuable information. This study is not yet recruiting participants, so you have time to consider your involvement. It aims to provide insights into the long-term impact of these treatments on patients like you, which could help improve future care for others with melanoma.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Participants with melanoma who enrolled in cohorts 6, 15, or 16 of study R3767-ONC- 1613 (NCT03005782)
• Key Exclusion Criteria:
• • None
• • Note: Other protocol-defined Inclusion/ Exclusion criteria may apply